I enrolled in the Revlimid (lenalidomide) vs. observation clinical trial (I'm in the observation arm). My numbers were rechecked prior to randomization and my M-spike was 1.1 g/dL. At the first follow up, it was 1.2 g/dL.
Because of the constraints of the study, I have to have the blood drawn within 24 hours of the doctor visit, so I don't have most of the results until after the visit (the SPEP takes about a week).
About 10 days before my last visit, I started having some left foot pain which seemed like a pretty common ailment called plantar fasciitis. I told my hematologist about it and that I was thinking of seeing a podiatrist. He didn't seem too concerned.
A week after my visit, I got my SPEP back and my M-spike was 1.5 g/dL. I have made a podiatry appointment but it's not for several weeks, and my foot is slowly getting worse, though still not terrible. I know that:
- My M-spike is going to bounce around and that doesn't usually mean much (in the study it has to go up more than 25% from baseline two visits in a row before they consider it significant).
- My cytogenetics are standard risk (IgH translocation and nothing else)
- I just had the full skeletal survey plain x-rays and the MRI of the spine & pelvis 3 months ago and they were fine
- Bone lesions are way more common in the spine & pelvis than the extremities
- My foot symptoms are almost classic for plantar fasciitis.
I'm sure this is a common reaction early on, but do people get past it? How?
I feel like I'm seeing everything through a new pair of glasses called myeloma, and they distort everything I see in one way or another. Unfortunately, I can't take them off.